Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Connor

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Blood Advances|November 12, 2021
Coping strategies in patients with acute myeloid leukemiaHermioni L Amonoo, Monica H Bodd, Matthew J Reynolds, et al.
Mbio|December 12, 2023
Gut microbiome and antibiotic resistance effects during travelers' diarrhea treatment and preventionKevin S Blake, Drew J Schwartz, Srinand Paruthiyil, et al.
Journal for Immunotherapy of Cancer|July 21, 2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in bloodJennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Blood Advances|November 12, 2021
Coping strategies in patients with acute myeloid leukemiaHermioni L Amonoo, Monica H Bodd, Matthew J Reynolds, et al.
Mbio|December 12, 2023
Gut microbiome and antibiotic resistance effects during travelers' diarrhea treatment and preventionKevin S Blake, Drew J Schwartz, Srinand Paruthiyil, et al.
Journal for Immunotherapy of Cancer|July 21, 2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in bloodJennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 5